RESEARCH OF FLAVONOIDS OF SWEET-SCENT MARIGOLD (TAGETES LUCIDA CAV.)

Abstract

Introduction. In recent years, there has been a growing interest in studies of the binding function of serum albumin (BFSA) in various pathological conditions. However, changes in BFSA in chronic diseases remain poorly studied. Given the existing evidence of the impact of serum albumin transport disorders on the effectiveness of drug treatment, it is important to study the relationship of BFSA disorders with various pathological processes accompanied by long-term drug treatment. Among such diseases, hypertension (HTN) and various comorbid conditions arouse interest.

The aim of the research – to evaluate the relationships between changes in BFSA and indicators of liver function in HTN in combination with concomitant non-alcoholic steatohepatitis (NASH) and type 2 diabetes mellitus (DM) and to propose drug correction of the detected changes.

Research Methods. Three groups of patients with stage II HTN with a degree of arterial hypertension of 2–3 were examined. The first group included 28 people without concomitant diseases, the second group included 48 patients with concomitant NASH, and the third group included 47 people with NASH and type 2 diabetes. Groups 2 and 3, in turn, were divided into two subgroups (A and B). Patients of subgroup A – received basic HTN therapy and, in addition, the Antral drug of 1 tablet 3 times a day for 60 days, of subgroup B – only basic HTN therapy. All patients underwent a standard clinical examination, as well as had their BFSA and liver indicators inspected: the activity of alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltranspeptidase (GGT), alkaline phosphatase (ALP), thymol turbidity test (TTT) and total serum bilirubin (T Bil) in blood. The comparison group consisted of 25 practically healthy individuals.

Results and discussion. Increased activity of GGT, ALP, TTT indicators and total serum bilirubin was observed in patients of group 1, and a positive correlation between the average strength of BFSA and total bilirubin was observed. In group 2 there was a decrease of BFSA and an increase of all the studied indicators, in addition, negative correlations of its average strength with AST and ALP were observed. Group 3 showed an even more significant decrease of BFSA and liver function indicators, as well as negative correlations of the average strength of BFSA with ALT and TTT and a strong connection with ALP. In patients of both subgroups treated with Antral, compared with the subgroups without the use of hepatoprotectant, BFSA increased and the studied increased levels of biochemical indicators decreased and the strength of correlations of BFSA with all indicators increased. This may be due to the positive effect of Antral on the functional state of the liver.

Conclusions. The use of Antral in patients with HTN in combination with NASH and NASH and type 2 DM leads to an improvement in the indicator of BFSA and liver function.